Skip to content

PHARMOVAN

Active
Public limited companyfounded 198936 yrs activeAarschotsesteenweg 537, 3012 Leuven, BelgiumKBO/BCE: BE 0439.974.380
Summary

PHARMOVAN has been active since 1989 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €249,395 and a net result of €127,911. Equity remains stable across the filed fiscal years (±0% per year). Its solvency ranks better than 53% of 10645 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Risk analysisWatch ReportCompare
PHARMOVANActiveChecked score 76/100
Risk analysis ReportCompare

Overview

What they do
Retail sale of pharmaceutical products
NACE 47730Warehousing and support activities for transportation NACE 52310
1 site
How big
€626,313total assets 2025
Staff
1.5 FTE
Equity
€249,395
Profit
€127,911
Turnover not published (abridged schema)
Financially healthy?
76 Excellent Checked score 2025
Bankruptcy chance 12 m
0.3%
Who decides
Parent
MANAGEMENT CAROLINE VANDECASTEELE · 100%
Accounts 58 d early0 of 10 deeds read
Why 76- Higher-failure-rate sector+ Long track record+ Annual accounts: healthy financial profile+ Lower-risk legal formLatest accounts filed on timeShow the evidence

Checked score

Score 2025
76 / 100
Excellent
Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability94▼-6
Solvency65▲+3
Growth52▼-26
Track record100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €18,000 at 30 days acceptable
Liquidity ample (current ratio 1.8 against 1.8 in 2024; short-term debt: 51.6% and cash: 23.3% of total assets), but 60.2% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 36 years 0 40 y
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
39.8%
Return on assets
20.4%
Age of the figures
9 mo
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-06-2026, 58 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
58 d early
2024
58 d early
2023
20 d late
2022
17 d late
2021
17 d early
2020
3 d late
2019
33 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 9 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 14 July (5 of the last 5 filed years within 41 days of that day).
Companies Code · seven months
Position in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · abbreviated…
  2. Annual accounts filedfiscal year 2024 · abbreviated…
  3. Highest result since 2018net €179,564 ▲22.1%

Key points

  • Positive: 8 profitable years in a rowprofit 2025: €127,911 8 years View
  • Positive: Among the best 20% on net resultsector median €28,475 · 10,633 companies €127,911 View
  • Controlled by MANAGEMENT CAROLINE VANDECASTEELE 100% View
  • Caution: Result fell in 2025from €179,564 to €127,911 ▼ 28.8% View

By topic

Financials

Fiscal year
2025
Total assets
€626,313
Profit
€127,911
Solvency
39.8%
Total assets▼ 7.4%
Net result
20182025
Go to Financials

Timeline

Events
12
Since
2017
Next accounts
by 31-07-2027
  1. 03-06-2026Annual accounts filed
  2. 03-06-2025Annual accounts filed
  3. 31-12-2024Highest result since 2018
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
27-12-1989
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure